Rhumbline Advisers Silence Therapeutics PLC Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 841 shares of SLN stock, worth $4,415. This represents 0.0% of its overall portfolio holdings.
Number of Shares
841
Previous 754
11.54%
Holding current value
$4,415
Previous $13,000
61.54%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SLN
# of Institutions
73Shares Held
28.1MCall Options Held
300Put Options Held
2K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$15.9 Million7.16% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$14.9 Million2.57% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.66MShares$14 Million3.3% of portfolio
-
Redmile Group, LLC San Francisco, CA1.9MShares$9.97 Million2.26% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.15MShares$6.03 Million1.12% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $188M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...